Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.42 |
| ▸ | TTR | P02766 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699195 | 0.83 | PARP1 (0.49) | PARP1TTR | |
| SCHEMBL10414534 | 0.81 | PARP1 (0.47) | PARP1TTR | |
| SCHEMBL10414532 | 0.81 | PARP1 (0.47) | PARP1TTR | |
| SCHEMBL20810556 | 0.78 | FAAH (0.46) | PARP1 | |
| SCHEMBL7615559 | 0.77 | PARP1 (0.53) | PARP1TTR | |
| SCHEMBL7785229 | 0.76 | PARP1 (0.44) | PARP1TTR | |
| SCHEMBL20810331 | 0.75 | PARP1 (0.39) | PARP1GRIK1GRIK2TTR | |
| SCHEMBL28179497 | 0.75 | TTR (0.59) | PARP1TTR | |
| SCHEMBL6170785 | 0.74 | GLA (0.56) | PARP1 | |
| SCHEMBL6170786 | 0.74 | GLA (0.56) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589067-B2 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080039406-A1 | 3,6-BRIDGED TYLOSIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | CYP2B6, CYP2D6, ABCB11 | PARP1 3253/4885HTR2A 3602/4885GRIK1 4440/4885 |
| US-20080039406-A1 | 3,6-BRIDGED TYLOSIN DERIVATIVES | ABCB11, ABCB1, CYP2B6 | PARP1 4713/4885HTR2A 4055/4885GRIK1 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.